Canadian Immunization Guide: Table of updates
On this page
Table of updates (2024 to present)
Date | Chapter | Updates |
---|---|---|
2025-04 | Pneumococcal vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): |
2025-04 | Respiratory syncytial virus (RSV) vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): |
2025-04 | Measles vaccines | This chapter was updated based on the following statement from the National Advisory Committee on Immunization (NACI):
|
2025-03 | Meningococcal vaccines | The chapter has been updated to align with the Summary of updates in the Canadian Immunization Guide as of March 31, 2025: Updated guidance on quadrivalent conjugate meningococcal vaccines available in Canada. |
2025-02 | Rabies vaccines | The chapter was updated to clarify bat exposure (i.e., when there has been direct contact between a person and a bat, or, much less commonly, when saliva from the bat enters into an open wound or mucous membrane). |
2025-02 | COVID-19 vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI):
|
2024-12 | Poliomyelitis (polio) vaccines | The chapter was updated to provide clarification on guidance on the immunization of individuals previously immunized with bivalent oral polio vaccine (bOPV). |
2024-11 | Smallpox and mpox vaccines | This chapter was updated to include a new recommendation issued by the Public Health Agency of Canada, recommending immunization with Imvamune® for Canadian healthcare professionals in advance of deployment to support the mpox clade I outbreak in countries where there is a level 2 travel health notice for mpox. Chapters revised to reflect these changes: Immunization of Travellers and Immunization of Workers. |
2024-11 | Japanese encephalitis vaccine | The Booster doses and re-immunization section has been updated with new guidance from the Committee to Advise on Tropical Medicine and Travel (CATMAT):
Chapter revised to reflect these changes: Immunization of travellers |
2024-11 | Immunization of immunocompromised persons | This chapter was updated to incorporate guidance from the COVID-19 vaccines and Pneumococcal vaccines chapters in Part 4 and the following statements from the National Advisory Committee on Immunization (NACI): |
2024-10 | Basic immunology and vaccinology | This chapter has undergone a complete update to reflect current insights in the evolving fields of immunology and vaccinology. Building upon the foundational concepts previously introduced in the chapter, this update aims to capture the current state of understanding and provide general information on emerging research areas within these domains. |
2024-10 | Pneumococcal vaccines | Erratum: In the Hematopoietic stem cell transplantation (HSCT) section, the following change has been made: "Pneumococcal vaccination should be started at 3 to 9 months after HSCT with 3 doses of Pneu-C-20 vaccine administered at least 4 weeks apart, followed by 1 dose of Pneu-C-20 vaccine 12 to 18 months post-transplant (6 to 12 months after the last dose of Pneu-C-20 vaccine) The segment "…or when the HSCT recipient reaches 2 years of age" has been deleted from this recommendation. This was a remnant of an earlier pneumococcal vaccine recommendation relating to PPV23. The 2-year age restriction should not apply to the conjugate vaccine. |
2024-09 | COVID-19 vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): |
2024-09 | Smallpox and mpox vaccines | This chapter was updated based on the following statement from the National Advisory Committee on Immunization (NACI): |
2024-08 | Respiratory syncytial virus (RSV) vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): Chapters revised to reflect these changes: Immunization of adults, Immunization of patients in health care institutions, Immunization of persons with chronic diseases and Recommended immunization schedules. |
2024-07 | Influenza vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI):
|
2024-07 | Human papillomavirus (HPV) vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): New recommendations:
Chapters revised to reflect these changes: Principles of vaccine interchangeability, Timing of vaccine administration, Immunization of adults and Immunization in pregnancy and breastfeeding |
2024-06 | Respiratory syncytial virus (RSV) | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): Chapters revised to reflect these changes: Immunization of infants born prematurely, Immunization in pregnancy and breastfeeding, Immunization of persons with chronic diseases, Varicella (chickenpox) vaccines, Blood products, human immunoglobulin and timing of immunization and Recommended immunization schedules. |
2024-06 | COVID-19 vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI):
|
2024-05 | Meningococcal vaccines | This chapter has been updated to align with the National Advisory Committee on Immunization (NACI) update on invasive meningococcal disease (IMD) epidemiology and program-relevant considerations for preventing IMD in individuals at high risk of exposure (CCDR). |
2024-05 | Pneumococcal vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI):
For NACI recommendations for the prevention of invasive pneumococcal disease using Prevnar®13 (PNEU-C-13) and the pneumococcal polysaccharide vaccine Pneumovax®23 (PNEU-P-23), refer to the archived Pneumococcal vaccines chapter. Chapters revised to reflect these changes: Immunization of persons with chronic diseases, Immunization of infants born prematurely, Recommended immunization schedules, Immunization of adults, Immunization in pregnancy and breastfeeding and Timing of vaccine administration. |
2024-04 | Immunization in pregnancy and breastfeeding | This chapter was updated to incorporate guidance from the COVID-19 vaccines chapter, the smallpox and mpox (monkeypox) vaccines chapter, and the following National Advisory Committee on Immunization (NACI) statements: |
Table of updates (2021 to 2023)
Date | Chapter | Updates |
---|---|---|
2023-12 | COVID-19 vaccines | This chapter was updated to further reflect the authorization of Novavax Nuvaxovid XBB.1.5 vaccine. |
2023-12 | Influenza vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI):
|
2023-12 | COVID-19 vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): |
2023-10 | COVID-19 vaccines | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): |
2023-10 | Herpes zoster (shingles) vaccine | This chapter was revised to reflect the discontinuation of Zostavax®, the live-attenuated zoster vaccine (LZV), in 2023. |
2023-09 | Immunization of travellers | This chapter was updated to align with the Statement on the Use of Booster Doses of Yellow Fever Vaccine and the Statement on Prevention of Japanese Encephalitis, both developed by the Committee to Advise on Tropical Medicine and Travel (CATMAT). Additionally, a new section on COVID-19 vaccine has been added which includes recommendations based on the CATMAT Statement on COVID-19 and International Travel. |
2023-09 | Japanese encephalitis vaccine | Recommendations for use of Japanese Encephalitis (JE) vaccine have been updated based on the Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement on Prevention of Japanese Encephalitis. |
2023-09 | Ebola virus vaccine | This new chapter was developed based on the following statements:
Chapters revised to reflect these updates: Immunization of adults, Immunization of workers, Immunization in pregnancy and breastfeeding. |
2023-07 | Recommended immunization schedules | Clarifications were made to Table 5 to better align with information provided in Part 4 chapters. |
2023-06 | Smallpox and mpox (monkeypox) vaccine | The chapter was revised to align with the World Health Organization's preferred term of 'mpox' for monkeypox disease. Additionally, the "Safety and adverse events" section was updated to expand on the safety of Imvamune vaccine based on data from clinical trials. |
2023-06 | Immunization of Workers | This chapter was updated based on the following statement from the National Advisory Committee on Immunization (NACI): |
2023-06 | COVID-19 vaccine | This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI):
For additional information on these updates, including a list of selected references, refer to Summary of updates in the Canadian Immunization Guide as of June 27, 2023: Updated guidance on COVID-19 vaccines in Canada. |
2023-05 | Influenza vaccine | This chapter was developed based on the following statements from the National Advisory Committee on Immunization (NACI):
|
2023-05 | Vaccine administration practices | The section on “Route, site and technique for vaccine administration” was updated to expand on the administration of intradermal injections. |
2023-04 |
Part 5: Passive Immunization | This chapter entitled "Part 5: Passive Immunization" has been removed from the Canadian Immunization Guide and the content has been moved elsewhere within the Guide. Information on standard immunoglobulin has been moved to the following chapters:
Information on specific immunoglobulins has been moved to the following chapters:
The information on botulism antitoxin and botulism immunoglobulin as well as the information on cytomegalovirus immunoglobulin has been moved to Table 2 in the Contents of Immunizing Agents Authorized for Use in Canada in Part 1. |
2023-03 | Respiratory syncytial virus | This new chapter was developed based on the statement, Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants from the National Advisory Committee on Immunization (NACI). This chapter replaces the Respiratory syncytial virus monoclonal antibody section in the former Part 5 Passive Immunization. Chapters revised to reflect these updates: Adverse events following immunization, Immunization of immunocompromised persons, Immunization of infants born prematurely, Immunization of patients in health care institutions, Immunization of persons with chronic diseases |
2023-03 | COVID-19 vaccine | This chapter was updated based on the following statement from the National Advisory Committee on Immunization (NACI):
Additionally, the following content was added:
|
2023-03 | COVID-19 vaccine | This chapter was updated based on the statements from the National Advisory Committee on Immunization (NACI): |
2023-03 | Yellow fever vaccine | March 2023: This chapter has been reviewed and revised to align with the Statement on the use of booster doses of yellow fever vaccine from the Committee to Advise on Tropical Medicine and Travel (CATMAT). Revisions to this chapter include:
Chapter revised to reflect this update: Immunization of adults |
2023-02 | Contraindications and precautions | This chapter was updated with guidance on contraindications and precautions associated with allergies to a vaccine component or its container. |
2023-02 | This chapter was updated to align with changes made to:
|
|
2023-02 | Poliomyelitis vaccine | The chapter was updated to include information on circulating vaccine-derived poliovirus 2 (cVDPV2) outbreaks outside of Canada. Guidance on the immunization of individuals previously immunized with bivalent oral polio vaccine (bOPV) is provided. Chapters revised to reflect these updates: Immunization of persons new to Canada, immunization of travellers |
2022-12 | COVID-19 vaccine | This chapter was updated based on the following statements from the National Advisory Committee on Immunization (NACI):
The following additional update was also made:
|
2022-12 | Smallpox and monkeypox vaccine | This chapter was updated to reflect guidance based on current evidence and the National Advisory Committee on Immunization's (NACI's) expert opinion on the use of Imvamune® in the context of monkeypox outbreaks in Canada. For this information, refer to the following:
|
2022-10 | COVID-19 vaccine | This chapter was updated based on the following statements from the National Advisory Committee on Immunization (NACI):
|
2022-08 | COVID-19 vaccine | The following updates were made:
For current product monographs please refer to Health Canada's Drug Product Database. *For additional information on these updates, including a list of selected references, refer to Summary of updates in the Canadian Immunization Guide as of August 29, 2022: Updated guidance on COVID-19 vaccines in Canada. |
2022-06 | COVID-19 vaccine | The following updates were made:
For additional information on these updates, including a list of selected references, refer to Summary of updates in the Canadian Immunization Guide as of June 21, 2022: Updated guidance on COVID-19 vaccines in Canada. |
2022-06 | Part 5 - Passive Immunization | June 2022: The content on respiratory syncytial virus (RSV) monoclonal antibody (palivizumab [SYNAGIS®) has been removed from this chapter. For information on the use of palivizumab, refer to the National Advisory Committee on Immunization (NACI) Statement on Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
2022-06 | COVID-19 vaccine | This chapter was updated based on the following statements from the National Advisory Committee on Immunization (NACI):
The following additional updates were also made:
For additional information on these updates, including a list of selected references, refer to Summary of updates in the Canadian Immunization Guide as of June 3, 2022: Updated guidance on COVID-19 vaccines in Canada. |
2022-05 | Hepatitis B vaccine | May 2022 - Erratum: The footnotes in Figure 1: Management of Individuals with Percutaneous or Mucosal Exposure to an Infected or High-Risk Source and the accompanying text description for the figure have been revised to align with the corresponding figure in Protocole d'immunisation du Québec, 5e édition (2009) from which it was adapted. |
2022-05 | Immunization of persons with chronic diseases | This chapter has been reviewed and updated with revisions, such as:
|
2022-05 | Immunization of immunocompromised persons | The chapter was updated to include guidance on vaccination with COVID-19 vaccines for individuals pre- and post-hematopoietic stem cell transplantation (HSCT) and for chimeric antigen receptor (CAR) T cell therapy recipients. |
2022-04 | COVID-19 vaccine | This chapter was updated with the following content:
|
2022-04 | Immunization of persons new to Canada | This chapter was updated to include a new section on COVID-19 vaccine with recommendations for individuals planning to live, work or study in Canada who have received 1 or 2 doses of a non-Health Canada authorized vaccine. |
2022-03 | COVID-19 vaccine | This chapter was updated based on the following statement from the National Advisory Committee on Immunization (NACI):
|
2022-03 | COVID-19 vaccine | This chapter was updated based on the following statements from the National Advisory Committee on Immunization (NACI):
|
2022-01 | COVID-19 vaccine | This chapter was updated based on the following statements from the National Advisory Committee on Immunization (NACI):
The COVID-19 vaccine recommendations section for "Individuals previously infected with SARS-CoV-2" has been updated and additional information provided in the rationale and evidence. Additionally, the "Vaccine safety and adverse events" and "Precautions" sections were updated to reflect:
|
2021-12 | COVID-19 vaccine | This new chapter was developed based on the Recommendations on the use of COVID-19 vaccines and the Interim guidance on booster COVID-19 vaccine doses in Canada statements from the National Advisory Committee on Immunization (NACI). |
2021-11 | Hepatitis A vaccine | The immunoglobulin dosage for Hepatitis A pre-exposure and post-exposure prophylaxis was increased based on the Product Monograph update for GamaSTAN®which is available on Health Canada's Drug Product Database. Chapter revised to reflect this change: Passive Immunization |
2021-11 | Typhoid vaccine | A change has been made in the "Drug-drug and drug-food interactions" sub-section regarding the interval between the oral typhoid vaccine and certain antibiotics and antimalarials. Chapter revised to reflect this change: Contraindications and Precautions |
2021-11 | Contraindications and Precautions | This chapter was completely reviewed with several revisions that include:
Chapters revised to reflect this change: Immunization of Persons with Chronic Diseases, Yellow Fever Vaccine |
2021-08 | Mumps vaccine | This chapter has been updated to align with the National Advisory Committee on Immunization Statement (NACI): Use of Measles-Mumps-Rubella (MMR) Vaccine for the Management of Mumps Outbreaks in Canada. Updates include:
|
2021-07 | Immunization in Canada | This chapter has been completely reviewed and updated to include additional information on immunization programs in Canada and the responsibilities of Federal, Provincial and Territorial immunization committees, advisory bodies, stakeholders, and networks in immunization policy and program development. |
2021-03 | Anaphylaxis and other Acute Reactions following Vaccination | EMERADE™, an EPINEPHrine autoinjector, has been added to Table 4: Dosage of intramuscular EPINEPHrine 1:1000 (1mg/mL), by age or weight |
2021-02 | Immunization of Persons with Chronic Diseases | The section on "Chronic inflammatory conditions" has been renamed "Autoimmune conditions" and has been updated to include information on COVID-19 mRNA vaccines. |
Table of updates (2018 to 2020)
Date | Chapter | Updates |
---|---|---|
2020-12 | Anaphylaxis and other acute reactions following vaccination | This chapter has been reviewed and updated with major revisions such as:
|
2020-09 | Measles Vaccine | The criterion for measles immunity was previously listed for travellers to destinations outside of North America. Due to the changes in global measles epidemiology, this criterion for measles immunity was changed to travellers to destinations outside of Canada. Chapters revised to reflect this change: Immunization of Travellers, and Immunization of Adults. |
2020-02 | Meningococcal Vaccine | Updated recommendations: The chapter has been updated to align with the National Advisory Committee on Immunization Statement (NACI): The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease. Updates include: MenB-fHBP vaccine may be considered as an option for use in individuals 10 years of age and older in situations when a serogroup B meningococcal vaccine should be offered:
MenB-fHBP vaccine may be considered as an option for individuals 10-25 years of age who are not at higher risk of meningococcal disease than the general population, but who wish to reduce their risk of invasive serogroup B meningococcal disease. |
2019-12 | Adverse Events Following Immunization *NEW CHAPTER* | The content on adverse events following immunization (AEFI) has been completely reviewed and moved from the Vaccine Safety and Pharmacovigilance chapter into its own chapter. |
2019-12 | Vaccine safety and pharmacovigilance | This chapter was completely reviewed with several revisions which expand on the previous content related to Canadian and international vaccine pharmacovigilance definitions, regulation, processes and stakeholders. The content on adverse events following immunization (AEFI) has been moved to its own chapter, Adverse Events Following Immunization. |
2019-06 | Immunization of Immunocompromised Persons | June 2019 - Erratum: The permissive use of MMRV vaccine in the post-transplantation vaccination of hematopoietic stem cell transplantation (HSCT) recipients has been removed from the text. Table 3 has been revised to reflect this change. MMR and univalent varicella vaccines should be used instead. May 2018 - The chapter has been reviewed and updated with major revisions such as:
Chapter revised to reflect this change: Contraindications, Precautions and Concerns |
2018-10 | Measles Vaccine |
The concentrations of anti-measles antibodies in human Ig products have shown trends of gradually declining and are no longer considered optimally protective using the previously recommended dosing strategies. The chapter features new dosing and route of administration for measles Ig PEP in susceptible infants and individuals who are immunocompromised or pregnant. |
2018-08 | Herpes Zoster (Shingles) Vaccine | Updated recommendation: This chapter has been revised to reflect NACI's Updated recommendations on the use of herpes zoster vaccines. Most sections were revised to include information and practice recommendations for the new recombinant zoster vaccine (RZV) which is now available in Canada. Changes include:
|
2018-08 | Immunization in pregnancy and breastfeeding | August 2018 - [Errata] This chapter was partially updated to replace Table 1: Summary of Recommendations for Immunization in Pregnancy and Breastfeeding - Inactivated vaccines. April 2018 - The chapter has been reviewed and updated to align with the updated NACI Statement on immunization in pregnancy with Tdap vaccine.
Additional updates include:
|
2018-08 | Meningococcal Vaccine | The chapter has been updated with minor revisions: Vaccine administration:
|
2018-03 | Pertussis vaccine | New recommendation: One dose of Tdap vaccine should be administered in every pregnancy, ideally between 27 and 32 weeks of gestation. Chapters revised to reflect this change: Principles of Combination vaccines, Recommended immunization schedules, Immunization of adults, Immunization in pregnancy and breastfeeding |
Table of updates (2015 to 2017)
Date | Chapter | Updates |
---|---|---|
2017-11 | Vaccine Administration Practices | The chapter has been reviewed and updated with major revisions, such as:
|
2017-05 | Timing of Vaccine Administration | The chapter has been reviewed and a new table has been added: "Table 1: Minimum age and minimum intervals between vaccine doses in healthy children less than 18 years of age". |
2017-04 | Contents of Immunizing Agents Available for Use in Canada | Information on the contents of immunizing agents (e.g., adjuvants, preservatives, etc.) has been moved from the Basic Immunology and Vaccinology chapter to this chapter. |
2017-04 | Basic Immunology and Vaccinology | The chapter has been reviewed and updated with minor revisions. |
2017-04 | Cholera and Enterotoxigenic Escherichia coli (ETEC) Travellers' Diarrhea Vaccine | This chapter has been reviewed and revised to align with the Statement on Travellers' Diarrhea from the Committee to Advise on Tropical Medicine and Travel (CATMAT). |
2017-04 | Typhoid Vaccine | This chapter has been reviewed and revised to align with the Statement on International Travellers and Typhoid from the Committee to Advise on Tropical Medicine and Travel (CATMAT). |
2017-04 | Immunization of Travellers | This chapter has been reviewed and revised to align with the updated chapters on Typhoid Vaccine and Cholera and Enterotoxigenic Escherichia coli (ETEC) Traveller's Diarrhea Vaccine. |
2017-03 | Hepatitis B | Updated recommendation: For immunocompromised individuals, initial annual monitoring of HB antibody levels may be considered. Chapter(s) revised to reflect this change: Immunization of Immunocompromised Persons Table 3: Recommended Dosages and Schedules for Hepatitis B-Containing Vaccines -The dosage of Recombivax HB® for infants (of HB-negative mothers) to children less than 11 years of age has been changed from 0.25mL to 0.5mL. A footnote has been added to Table 3 to explain this change. |
2017-03 | Storage and Handling of Immunizing Agents | The chapter has been reviewed and revised to align with the Public Health Agency of Canada's National Vaccine Storage and Handling Guidelines for Immunization Providers 2015 |
2016-11 | Immunization of Immunocompromised Persons | An update has been made to the "Immunosuppressive therapy" section on immunizing infants following exposure to monoclonal antibodies during pregnancy or breastfeeding. Information regarding live rotavirus vaccine administration has been included in the updated content. Chapter(s) revised to reflect this change: Diphtheria Toxoid, Herpes Zoster Vaccine, Rotavirus and Yellow Fever Vaccine. |
2016-10 | Pneumococcal vaccine | New recommendation: On an individual basis, PNEU-C-13 vaccine may be recommended to immunocompetent adults aged 65 years and older not previously immunized against pneumococcal disease, for the prevention of community acquired pneumonia and invasive pneumococcal disease caused by the 13 pneumococcal serotypes included in the conjugate vaccine. When it is given, it should precede PNEU-P-23 vaccine. |
2016-09 | Influenza Vaccine | Updated recommendation: The current evidence does not support a recommendation for the preferential use of LAIV in children and adolescents 2-17 years of age. |
2016-09 | Influenza Vaccine | New recommendation: egg allergic individuals may be vaccinated against influenza using the low ovalbumin-containing live attenuated influenza vaccine (LAIV) licensed for use in Canada. Chapter revised to reflect this change: Contraindications and Precautions |
2016-05 | Influenza Vaccine | New product: Fluzone®High-Dose influenza vaccine has been approved for use in Canada in adults ≥65 years of age. |
2016-05 | Influenza Vaccine | New recommendation: NACI now includes adults with neurologic or neurodevelopment conditions among the groups for whom influenza vaccination is particularly recommended. |
2016-09 | Hepatitis A vaccine | New recommendation: Hepatitis A (HA) vaccine may be administered to persons six months of age and older. |
2016-09 | Hepatitis A vaccine | New recommendation: For post-exposure prophylaxis within 14 days of exposure of susceptible adults 60 years of age and older who are household or close contacts of a case, Ig may be provided in addition to HA vaccine. |
2016-09 | Hepatitis A vaccine | New recommendation: Immunization with HA vaccine may be considered for all individuals receiving repeated replacement of plasma-derived clotting factors. |
2016-09 | Hepatitis A vaccine | New recommendation: For post-exposure prophylaxis of susceptible individuals with chronic liver disease, Ig should be provided within 14 days of exposure in addition to HA vaccine. |
2017-05 | Human papillomavirus vaccine | New recommendation: HPV9 vaccine may be administered to immunocompetent males and females 9 to 14 years of age according to a 2-dose or 3-dose immunization schedule. The second dose of HPV9 vaccine in a 2-dose schedule should not be administered earlier than 24 weeks (6 months) following the first dose. Immunocompromised individuals should continue to receive a 3-dose immunization schedule, as previously recommended. Chapter revised to reflect this change: Recommended Immunization Schedules |
2016-07 | Human papillomavirus vaccine | New recommendation: Gardasil®9 (HPV9 vaccine) has recently been authorized for use in Canada for the prevention of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58-related cancers and anogenital warts |
2016-07 | Human papillomavirus vaccine | New recommendation: Any of the currently authorized HPV vaccines in Canada can be used according to the recommended HPV immunization schedules Chapter revised to reflect this change: Immunization of Adults |
2017-04 | Principles of Combination Vaccines | The chapter has been reviewed and updated with minor revisions. |
2016-09 | Varicella vaccine | Updated recommendation: Susceptibility and Immunity section updated to provide further information about individuals who require immunization with varicella vaccine Chapter(s) revised to reflect this change: Immunization of Workers |
2016-09 | Varicella vaccine | Updated recommendation: Varicella immune globulin recommendations updated to allow for product administration up to 10 days since last exposure for the purpose of disease attenuation |
2016-09 | Varicella vaccine | A clarification on the minimum interval between two varicella-containing vaccines has been made in accordance with the information available in the Health Canada approved product monographs. NACI considers the minimum interval of 4 weeks to be acceptable in exceptional circumstances. If the second dose of varicella-containing vaccine is administered at an interval of less than 4 weeks, it should be repeated. NACI continues to recommend an interval between two varicella-containing vaccines of at least 3 months for children less than 13 years of age and 6 weeks for individuals 13 years of age and older. Chapters revised to reflect this change: Timing of Vaccine Administration, Measles, Mumps |
Table of updates (2012 to 2014)
Date | Chapter | Updates |
---|---|---|
2012-11 | Herpes Zoster (shingles) vaccine | A herpes zoster vaccine has been authorized for use in adults aged 50 years and older. |
2012-11 | Herpes Zoster (shingles) vaccine | One dose of herpes zoster vaccine is recommended for adults over 60 years of age without contraindications to the vaccine. |
2014-03 | Herpes Zoster (shingles) vaccine | New recommendation: Herpes zoster (HZ) vaccine may be administered to individuals 50 years of age and older with a prior history of HZ disease with at least one year recommended following the last episode of HZ. |
2014-03 | Herpes Zoster (shingles) vaccine | New recommendation: In general, herpes zoster (HZ) vaccine should not be given to individuals with primary or acquired immune deficiency but may be administered to individuals on low dose immunosuppression. |
2014-03 | Herpes Zoster (shingles) vaccine | New recommendation: Herpes zoster (HZ vaccine) can be co-administered (using a different site) with pneumococcal vaccine. |
2014-10 | Human Papillomavirus (HPV) vaccine | New recommendation: HPV2 and HPV4 vaccines may be administered to non-immunocompromised, non-HIV infected, individuals 9-14 years of age as two separate 0.5 mL doses at months 0 and 6-12. A two dose schedule is also sufficient for individuals 15 years of age and older who received the first vaccine dose between 9-14 years when the second dose is administered at least 6 months after the first dose. |
2012-11 | Meningococcal vaccine | Recommendations for post-exposure immunoprophylaxis of close contacts of IMD who have been previously immunized have been provided. |
2012-11 | Meningococcal vaccine | Schedules (including booster doses) have been revised for high risk individuals as has the list of high risk individuals. |
2014-10 | Meningococcal vaccine | New product: A new quadrivalent conjugate meningococcal vaccine for serogroups A, C, Y, and W-135 (Men-C-ACYW-TT) has become available. |
2014-10 | Meningococcal vaccine | New product: A multi-component meningococcal vaccine (4CMenB) for serogroup B has become available. |
2012-11 | Pertussis vaccine | A new combination vaccine containing tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) has become available. |
2012-11 | Pertussis vaccine | Two new combination vaccines containing tetanus toxoid, reduced diphtheria toxoid, reduced acellular pertussis, and inactivated poliomyelitis vaccines (Tdap-IPV) have become available. |
2012-11 | Pertussis vaccine | A new combination vaccine containing diphtheria and tetanus toxoids, acellular pertussis, hepatitis B, inactivated poliomyelitis and Haemophilus influenzae type b vaccine (DTaP-HB-IPV-Hib) has become available for primary immunization of infants and young children. |
2012-11 | Pertussis vaccine | The combination vaccine containing diphtheria and tetanus toxoids, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b vaccine (DTaP-IPV-Hib) has become available in a pre-mixed format. |
2012-11 | Pertussis vaccine | A new recommendation for one dose of Tdap vaccine in adults, prioritizing adults who are in contact or anticipate contact with infants (e.g., parents, grandparents, childcare providers). |
2012-11 | Pertussis vaccine | One dose of combined diphtheria, tetanus, acellular pertussis containing vaccine (Tdap) can be offered to pregnant women (≥26 weeks of gestation) who have not been previously vaccinated against pertussis in adulthood. |
2012-11 | Pertussis vaccine | In special circumstances, such as a regional outbreak situation, immunization with Tdap may be offered to pregnant women (≥26 weeks of gestation) irrespective of their immunization. |
2014-01 | Pertussis vaccine | New recommendation: One dose of combined diphtheria, tetanus, acellular pertussis containing vaccine (Tdap) can be offered to pregnant women (≥26 weeks of gestation) who have not been previously vaccinated against pertussis in adulthood. |
2014-01 | Pertussis vaccine | New recommendation: In special circumstances, such as a regional outbreak situation, immunization with Tdap may be offered to pregnant women (≥26 weeks of gestation) irrespective of their immunization. |
2012-11 | Pneumococcal vaccine | Two new conjugate pneumococcal vaccines have become available: pneumococcal conjugate 10-valent (Pneu-C-10) and pneumococcal conjugate 13-valent (Pneu-C-13). |
2012-11 | Pneumococcal vaccine | Pneumococcal conjugate 7-valent (Pneu-C-7) vaccine is no longer available in Canada. |
2012-11 | Pneumococcal vaccine | Pneumococcal vaccination schedules have been updated. |
2014-03 | Pneumococcal vaccine | New recommendation: Individuals who required medical attention for asthma in the past 12 months should be vaccinated using the pneumococcal vaccine (conjugate vs. polysaccharide) and schedule recommended for their age group. |
2014-03 | Pneumococcal vaccine | New recommendation: PNEU-C-13 should be administered to adults with immunocompromising conditions. |
2014-10 | Pneumococcal vaccine | New recommendation: Adults 65 years or greater, regardless of risk factors, should receive one dose of Pneu-P-23 vaccine. |
Page details
- Date modified: